Latest news with #Obesity
Globe and Mail
6 hours ago
- Business
- Globe and Mail
Could GLP-1 Drugs Potentially Help Treat Cancer? 1 Promising Study Suggests They Might
Key Points Obesity is linked to many diseases, including cancer. A recent study found that tumors in mice shrank after they were administered tirzepatide. It could take years for GLP-1 drugs to obtain regulatory approval as cancer-related treatments. 10 stocks we like better than Eli Lilly › GLP-1 agonist drugs like Zepbound and Mounjaro from drugmaker Eli Lilly (NYSE: LLY) continue to rise in popularity as people are hopeful about the weight loss they can achieve with their help. But a growing number of studies suggest that they could be useful in indications beyond diabetes and weight loss. One particularly intriguing study involves cancer, and it reveals a potential role for GLP-1 agonists in that area of healthcare. If GLP-1 drugs end up obtaining approval as treatments related to oncology, that could unlock a massive new sales growth opportunity for them. That could make a stock like Eli Lilly an even better buy than it is today. Study finds tumors shrank in mice with the help of tirzepatide Previous studies have shown that when people shed weight, they reduce their risks of developing many illnesses, among them, cancer. But a recent study presented at the Endocrine Society's annual meeting found that GLP-1 agonists could have a more direct impact: They may also reduce the size of breast cancer tumors. The study was modest in scope and not on human patients: Its subjects were 16 mice. Those mice that received injections of tirzepatide (the active ingredient in both Zepbound and Mounjaro) for 16 weeks lost around 20% of their weight, which was comparable to the weight loss that humans achieve while on the drug. And their tumors shrank by around that percentage as well. "Researchers found that tumor volume was significantly correlated with body weight," reported ScienceDaily. But even though these results are promising, they are very preliminary. It would take years of studies on humans before a GLP-1 drug could conceivably obtain a label expansion for use in treating any type of cancer. However, there is hope that GLP-1 drugs can do more than just help with diabetes and weight reduction. Regulators did approve tirzepatide for the treatment of obstructive sleep apnea last year. And another study found that it can help reduce the risk of heart failure. As more research is done on GLP-1 drugs, the number of indications they can treat may grow significantly. And if tirzepatide is able to help treat cancer, it could make this already massive drug a sales behemoth for Eli Lilly. Business has been booming for Eli Lilly, and more growth is still ahead Eli Lilly has already been performing incredibly well, thanks in large part to its highly successful GLP-1 drugs. In the first three months of 2025, its sales soared by 45% year over year to $12.7 billion. Zepbound and Mounjaro combined to make up $6.2 billion of that tally. And what's exciting is that these drugs are still in their early growth stages. That's a big reason why Eli Lilly stock trades at a hefty premium of 65 times its trailing earnings. Its 5-year price-to-earnings growth (PEG) multiple of 1.2 indicates, however, that it may not be that expensive relative to its medium-term growth potential. Eli Lilly stock is a no-brainer buy Although the stock may not look cheap, Eli Lilly could be among the best long-term investments you can add to your portfolio today. If tirzepatide racks up more indications and Eli Lilly's already approved drugs reach greater numbers of people, its sales and profits are likely to rise in the years ahead. This year, the stock is up a modest 4% as the hype around it appears to have cooled. But if you're in it for the long haul, it would be hard to go wrong with Eli Lilly. It may just be one of the best growth stocks in the healthcare sector. Should you invest $1,000 in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
Yahoo
a day ago
- Business
- Yahoo
Obesity drugmaker Novo Nordisk cuts 2025 sales growth, operating profit outlook
COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk (NVO) warned on Tuesday that full-year sales and operating profit would grow less than previously expected, marking its second forecast cut of 2025. Novo stock fell 13% before the bell on Tuesday. The maker of weight-loss drug Wegovy is struggling to convince investors it can remain competitive in the obesity drug boom against U.S. rival Eli Lilly (LLY). Novo shares have fallen sharply over the past year. "The lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025," the company said in a statement. "This is related to lower growth expectations for Wegovy in the U.S. obesity market, lower growth expectations for Ozempic in the U.S. GLP-1 diabetes market, as well as lower-than-expected penetration for Wegovy in select IO markets," it said. Novo now expects 2025 sales growth of 8%-14% in local currencies, down from its previous 13-21% range. It also lowered its operating profit growth forecast to 10%-16%, from a prior outlook of 16-24%. Sign up for Yahoo Finance Daily Movers By subscribing, you are agreeing to Yahoo's Terms and Privacy Policy Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Independent
a day ago
- Health
- The Independent
Health expert on the risk factors for liver cancer
Liver cancer cases are projected to increase significantly, from 0.87 million in 2022 to 1.52 million by 2050, according to a Lancet Commission on Liver Cancer report. Rising obesity rates are a major contributing factor, with the proportion of liver cancer cases linked to obesity expected to double from 5 per cent to 11 per cent. Around three out of four cancers that start in the liver are hepatocellular carcinoma (HCC), which frequently develops in livers scarred by conditions such as excessive alcohol consumption or Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Early stages of liver cancer often show no symptoms, but advanced signs include jaundice, unexplained weight loss, and fatigue, with diagnosis typically involving ultrasound, CT, and MRI scans. Treatment options are diverse, ranging from curative surgeries like liver resection, transplant, or ablation for early detection, to other methods such as chemoembolisation for more advanced cases.
Reuters
a day ago
- Business
- Reuters
Obesity drugmaker Novo Nordisk cuts 2025 sales growth, operating profit outlook
COPENHAGEN, July 29 (Reuters) - Obesity drugmaker Novo Nordisk ( opens new tab warned on Tuesday that full-year sales and operating profit would grow less than previously expected, marking its second forecast cut of 2025. The maker of weight-loss drug Wegovy is struggling to convince investors it can remain competitive in the obesity drug boom against U.S. rival Eli Lilly (LLY.N), opens new tab. Novo shares have fallen sharply over the past year. "The lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025," the company said in a statement. "This is related to lower growth expectations for Wegovy in the U.S. obesity market, lower growth expectations for Ozempic in the U.S. GLP-1 diabetes market, as well as lower-than-expected penetration for Wegovy in select IO markets," it said. Novo now expects 2025 sales growth of 8%-14% in local currencies, down from its previous 13-21% range. It also lowered its operating profit growth forecast to 10%-16%, from a prior outlook of 16-24%.
Yahoo
a day ago
- Business
- Yahoo
Obesity drugmaker Novo Nordisk cuts 2025 sales growth, operating profit outlook
COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk warned on Tuesday that full-year sales and operating profit would grow less than previously expected, marking its second forecast cut of 2025. The maker of weight-loss drug Wegovy is struggling to convince investors it can remain competitive in the obesity drug boom against U.S. rival Eli Lilly. Novo shares have fallen sharply over the past year. "The lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025," the company said in a statement. "This is related to lower growth expectations for Wegovy in the U.S. obesity market, lower growth expectations for Ozempic in the U.S. GLP-1 diabetes market, as well as lower-than-expected penetration for Wegovy in select IO markets," it said. Novo now expects 2025 sales growth of 8%-14% in local currencies, down from its previous 13-21% range. It also lowered its operating profit growth forecast to 10%-16%, from a prior outlook of 16-24%. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
